{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"pla2g6-associated-neurodegeneration","columns":[],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":[],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"not available","narrativeSourceChanges":[],"records":0,"sourceGroups":{}},"features":[],"ledeHtml":"*PLA2G6*-associated neurodegeneration (PLAN) is an age-related continuum from infancy to adulthood comprising three broad age-related phenotypes: infantile PLAN, juvenile PLAN, and adult PLAN. Some individuals have intermediate phenotypes, suggesting that PLAN is more of a spectrum of disease rather than discrete phenotypes.","mondoId":"MONDO:0017998","node":{"canonicalSlug":"pla2g6-associated-neurodegeneration","comparisons":[],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","matchMethod":"automatic-preferred-title","name":"PLA2G6-Associated Neurodegeneration","paragraphs":["*PLA2G6*-associated neurodegeneration (PLAN) is an age-related continuum from infancy to adulthood comprising three broad age-related phenotypes: infantile PLAN, juvenile PLAN, and adult PLAN. Some individuals have intermediate phenotypes, suggesting that PLAN is more of a spectrum of disease rather than discrete phenotypes.","Infantile PLAN usually begins between ages six months and three years, presenting with truncal hypotonia, psychomotor delay, and plateauing or loss of previously acquired milestones. Most individuals have speech difficulties and do not achieve independent ambulation and/or initially have gait disturbance. Over time, affected persons develop both weakness and symmetric spastic tetraparesis that can cause discomfort, interfere with bracing or positioning, and often lead to contractures and scoliosis. Limb dystonia can also be present. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid; many children do not survive beyond their first decade.","Juvenile PLAN shows more phenotypic variability than infantile PLAN. In general, onset is in early childhood but can be as late as the end of the second decade. Presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are common. Although the disease course is fairly stable during early childhood, resembling static encephalopathy, it is followed by neurologic deterioration between ages seven and 12 years. Although life span is not known, it is expected to be longer than that of infantile PLAN.","Adult PLAN has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability."],"reviewed":"2026-04-14","scope":"exact","source":"GeneReviews","sourceExcerpt":"Summary / Clinical characteristics","sourceRelease":"2026-10-17 07:02:23.483889+00","upstream":"GeneReviews clinical characteristics","url":"https://www.ncbi.nlm.nih.gov/books/NBK1675/"},"ownColumnKeys":[],"publication":"published","relationships":[{"kind":"parent","label":"neurodegeneration with brain iron accumulation","mondoId":"MONDO:0018307","slug":"neurodegeneration-with-brain-iron-accumulation"},{"kind":"child","label":"neurodegeneration with brain iron accumulation 2B","mondoId":"MONDO:0012444","slug":"neurodegeneration-with-brain-iron-accumulation-2b"},{"kind":"child","label":"autosomal recessive Parkinson disease 14","mondoId":"MONDO:0013060","slug":"autosomal-recessive-parkinson-disease-14"},{"kind":"child","label":"neurodegeneration with brain iron accumulation 2A","mondoId":"MONDO:0024457","slug":"infantile-neuroaxonal-dystrophy"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"published"},"records":[],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1675/\" rel=\"noreferrer\">GeneReviews</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/12567\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0017998\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-preferred-title</dd><dt>Upstream attribution</dt><dd>GeneReviews clinical characteristics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>*PLA2G6*-associated neurodegeneration (PLAN) is an age-related continuum from infancy to adulthood comprising three broad age-related phenotypes: infantile PLAN, juvenile PLAN, and adult PLAN. Some individuals have intermediate phenotypes, suggesting that PLAN is more of a spectrum of disease rather than discrete phenotypes.</p><p>Infantile PLAN usually begins between ages six months and three years, presenting with truncal hypotonia, psychomotor delay, and plateauing or loss of previously acquired milestones. Most individuals have speech difficulties and do not achieve independent ambulation and/or initially have gait disturbance. Over time, affected persons develop both weakness and symmetric spastic tetraparesis that can cause discomfort, interfere with bracing or positioning, and often lead to contractures and scoliosis. Limb dystonia can also be present. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid; many children do not survive beyond their first decade.</p><p>Juvenile PLAN shows more phenotypic variability than infantile PLAN. In general, onset is in early childhood but can be as late as the end of the second decade. Presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are common. Although the disease course is fairly stable during early childhood, resembling static encephalopathy, it is followed by neurologic deterioration between ages seven and 12 years. Although life span is not known, it is expected to be longer than that of infantile PLAN.</p><p>Adult PLAN has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</p><p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1675/\" rel=\"noreferrer\">GeneReviews</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"pla2g6-associated-neurodegeneration","sourceDocuments":[{"name":"GeneReviews: PLA2G6-Associated Neurodegeneration","reviewed":"2026-04-14","source_release":"2026-10-17 07:02:23.483889+00","url":"https://www.ncbi.nlm.nih.gov/books/NBK1675/"},{"name":"GARD: PLA2G6-associated neurodegeneration","reviewed":null,"source_release":"2026-10-25T03:41:39Z","url":"https://rarediseases.info.nih.gov/diseases/12567"},{"name":"MONDO: PLA2G6-associated neurodegeneration","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0017998"}],"sourceNote":"","synonyms":["neurodegeneration with brain iron accumulation caused by mutation in PLA2G6","PLA2G6 neurodegeneration with brain iron accumulation","PLAN"],"takeawayHtml":"","title":"PLA2G6-associated neurodegeneration"},"schemaVersion":1}
